MenuClose
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletter

Recent coverage

ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlights

More tumor sites

Across disciplines

NADIM: five-year outcomesPerioperative chemotherapy plus nivolumab in resectable stage IIIA NSCLC: 5-year progression-free survival of 65%.Latest highlight, from The Lancet Oncology

The 2026 program

The OncoAlert Colloquium emblemThe OncoAlert ColloquiumThe year in review in oncology, one tumor group a day. Free for oncology professionals.

Listen to Oncology Here & Now

The newest Horizons discussionAdjuvant treatment challenges in early HR+/HER2− breast cancer, with Dr. Sibylle Loibl and Dr. Rupert Bartsch.

PE-PE

Abstract LBA88ESMO 2026GenitourinaryPicked by Dr. Gil Morgan and Dr. Toni Choueiri and Dr. Silke Gillessen and Dr. Neeraj Agarwal and Dr. Tian Zhang and Dr. Tom Powles and Dr. Brian Rini and Dr. Petros Grivas and Dr. Axel Merseburger and Dr. Aurelius Omlin and Dr. Andrea Apolo and Dr. Daniel Heng and Dr. Sumanta Pal and Dr. Enrique Grande and Dr. Hans Hammers and Dr. Natalia Gandur

What it tests: Perioperative pembrolizumab plus metastasis-directed therapy versus metastasis-directed therapy alone in oligometastatic RCC. Randomized phase 2 study.